单位:[1]Beijing Boren Hosp, Boren Biotherapy Translat Lab, State Key Lab Expt Hematol, Boren Clin Translat Ctr,Dept Hematol, Beijing 100070, Peoples R China[2]Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp, Tianjin 300020, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan 430030, Peoples R China内科学系血液内科华中科技大学同济医学院附属同济医院[4]Beijing Boren Hosp, Cytol Lab, Beijing 100070, Peoples R China[5]Beijing Boren Hosp, Dept Hematol, Beijing 100070, Peoples R China[6]Nanjing Iaso Biotherapeut Co Ltd, Nanjing 210000, Peoples R China[7]Beijing Boren Hosp, Med Lab, Beijing 100070, Peoples R China[8]Fujian Med Univ Union Hosp, Cent Lab, Fuzhou 350001, Peoples R China
National Key R&D Program of China [2019YFA0110200]; Tianjin Science Funds for Distinguished Young Scholars [17JCJQJC45800]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-003]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2018PT32034]; National Natural Science Foundation of China [81870090]
第一作者单位:[1]Beijing Boren Hosp, Boren Biotherapy Translat Lab, State Key Lab Expt Hematol, Boren Clin Translat Ctr,Dept Hematol, Beijing 100070, Peoples R China[2]Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp, Tianjin 300020, Peoples R China
通讯作者:
通讯机构:[2]Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp, Tianjin 300020, Peoples R China[8]Fujian Med Univ Union Hosp, Cent Lab, Fuzhou 350001, Peoples R China
推荐引用方式(GB/T 7714):
Tan Yue,Cai Haodong,Li Chuo,et al.A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL[J].BLOOD CANCER JOURNAL.2021,11(4):doi:10.1038/s41408-021-00465-9.
APA:
Tan, Yue,Cai, Haodong,Li, Chuo,Deng, Biping,Song, Weiliang...&Pan, Jing.(2021).A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.BLOOD CANCER JOURNAL,11,(4)
MLA:
Tan, Yue,et al."A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL".BLOOD CANCER JOURNAL 11..4(2021)